GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Cash Flow from Others

KAPA (Kairos Pharma) Cash Flow from Others : $1.66 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma Cash Flow from Others?

Kairos Pharma's cash flow from others for the three months ended in Sep. 2024 was $0.69 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Sep. 2024 was $1.66 Mil.


Kairos Pharma Cash Flow from Others Historical Data

The historical data trend for Kairos Pharma's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma Cash Flow from Others Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Others
- 0.14 0.41 0.06

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.94 0.02 0.02 0.69

Kairos Pharma Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.66 Mil.

Kairos Pharma Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Kairos Pharma Business Description

Traded in Other Exchanges
N/A
Address
2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.